Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals (MXC) receives an import approval permit for its COVID-19 treatment product, ArtemiC Rescue, into India
- The drug underwent a small batch trial import, passing all required regulatory motions to enable the sale of the product in India
- Additionally, it passed the Indian Customs’ import requirements, resulting in the approval for the sale of ArtemiC Rescue across India
- The company says it will continue to seek approvals for its product in a number of countries to provide support to COVID-19 patients
- MGC Pharmaceuticals is up 9.76 per cent, trading at 4.5 cents at 10:50 am AEDT
MGC Pharmaceuticals (MXC) has received an import approval permit for its ArtemiC Rescue product into India.
ArtemiC Rescue is MGC Pharma’s nutraceutical which has been proven to help alleviate symptoms associated with COVID-19. The clinically tested food supplement contains four natural-based ingredients, including Artemisinin, Curcumin, Boswellia serrata, and Vitamin C.
The drug underwent a small batch trial import, passing all required regulatory motions to enable the sale of the product in India, with the grant of a Food Safety and Standards Authority of India license.
On top of this, it passed the Indian Customs’ import requirements, resulting in the approval for the sale of ArtemiC Rescue across India.
With India’s population of more than 1.38 billion, which has seen daily soaring COVID-19 infections, MGC said the receipt of these approvals is a major step forward in the sale of ArtemiC Rescue.
Roby Zomer, co-founder and Managing Director of MGC Pharma, said the company is proud of achieving the milestone of being granted Indian import and distribution approval.
“Whilst the virus continues to mutate, as we have seen with Omicron, MGC Pharma is well placed to offer a solution on a worldwide scale to ease the pressure on national healthcare systems and aid the economic recovery of jurisdictions who have been widely affected by the pandemic,” said Roby Zomer.
The approval is hoped to further expand the global footprint for the sale and distribution of ArtemiC Rescue.
The company said it will continue to seek approvals for ArtemiC Rescue as a nutraceutical in a number of countries to provide support to COVID-19 patients.
Meanwhile, MGC Pharma said it’s been making progress on the development of CimetrA through ongoing clinical studies and applications for Emergency Use Authorisation in India.
MGC Pharmaceuticals was up 9.76 per cent, trading at 4.5 cents at 10:50 am AEDT.
